Search research articles
Contact Us
Filters
Showing results (61-70 of 84) with videos related to
Page
of 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 28, 2009
Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer
David Cunningham, Ian Chau, Deborah D Stocken, et al.
British Journal of Cancer
|
November 6, 2020
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial
Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 30, 2025
Impact of sex on efficacy and safety of 1st-line treatment with FOLFIRI plus cetuximab or bevacizumab in RAS/BRAF wildtype metastatic colorectal cancer - A subgroup analysis of the FIRE-3 (AIO KRK-0306) trial
Kathrin Heinrich, Sebastian Stintzing, Ludwig Fischer von Weikersthal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 2, 2008
Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001
Jürg Bernhard, Daniel Dietrich, Werner Scheithauer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 12, 2015
Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer
Dominik P Modest, Sebastian Stintzing, Ludwig Fischer von Weikersthal, et al.
The Lancet. Oncology
|
October 15, 2013
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial
Bernard Nordlinger, Halfdan Sorbye, Bengt Glimelius, et al.
Heart (British Cardiac Society)
|
September 30, 2015
Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality
Noemi Pavo, Markus Raderer, Martin Hülsmann, et al.
Annals of Surgery
|
February 9, 2012
Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983)
Halfdan Sorbye, Murielle Mauer, Thomas Gruenberger, et al.
Lancet (London, England)
|
March 25, 2008
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
Bernard Nordlinger, Halfdan Sorbye, Bengt Glimelius, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 19, 2020
Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial
Arndt Stahler, Sebastian Stintzing, Jobst C von Einem, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 84) with videos related to
Sort By:
Page
of 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 28, 2009
Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer
David Cunningham, Ian Chau, Deborah D Stocken, et al.
British Journal of Cancer
|
November 6, 2020
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial
Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 30, 2025
Impact of sex on efficacy and safety of 1st-line treatment with FOLFIRI plus cetuximab or bevacizumab in RAS/BRAF wildtype metastatic colorectal cancer - A subgroup analysis of the FIRE-3 (AIO KRK-0306) trial
Kathrin Heinrich, Sebastian Stintzing, Ludwig Fischer von Weikersthal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 2, 2008
Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001
Jürg Bernhard, Daniel Dietrich, Werner Scheithauer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 12, 2015
Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer
Dominik P Modest, Sebastian Stintzing, Ludwig Fischer von Weikersthal, et al.
The Lancet. Oncology
|
October 15, 2013
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial
Bernard Nordlinger, Halfdan Sorbye, Bengt Glimelius, et al.
Heart (British Cardiac Society)
|
September 30, 2015
Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality
Noemi Pavo, Markus Raderer, Martin Hülsmann, et al.
Annals of Surgery
|
February 9, 2012
Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983)
Halfdan Sorbye, Murielle Mauer, Thomas Gruenberger, et al.
Lancet (London, England)
|
March 25, 2008
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
Bernard Nordlinger, Halfdan Sorbye, Bengt Glimelius, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 19, 2020
Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial
Arndt Stahler, Sebastian Stintzing, Jobst C von Einem, et al.
Page
of 9